These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 32501118)

  • 1. RDM1 plays an oncogenic role in human ovarian carcinoma cells.
    Tong L; Cao W; Sheng J; Zhu E; Yu Y; Zhong T; Chen Y; Wang L
    Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):885-892. PubMed ID: 32501118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RDM1 plays an oncogenic role in human lung adenocarcinoma cells.
    Tong L; Liu J; Yan W; Cao W; Shen S; Li K; Li L; Niu G
    Sci Rep; 2018 Aug; 8(1):11525. PubMed ID: 30069034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of RDM1 enhances hepatocellular carcinoma progression via p53 and Ras/Raf/ERK pathways.
    Chen SL; Liu LL; Wang CH; Lu SX; Yang X; He YF; Zhang CZ; Yun JP
    Mol Oncol; 2020 Feb; 14(2):373-386. PubMed ID: 31670863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RDM1 promotes critical processes in breast cancer tumorigenesis.
    Chen Y; Sun Z; Zhong T
    J Cell Mol Med; 2019 Aug; 23(8):5432-5439. PubMed ID: 31222930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAD52 motif‑containing protein 1 promotes non‑small cell lung cancer cell proliferation and survival via cell cycle regulation.
    Xu G; Du J; Wang F; Zhang F; Hu R; Sun D; Shen J
    Oncol Rep; 2018 Aug; 40(2):833-840. PubMed ID: 29845285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of RDM1 with osteosarcoma progression via cell cycle and MEK/ERK signalling pathway regulation.
    Sheng J; Liu K; Sun D; Nie P; Mu Z; Chen H; Zhang Z
    J Cell Mol Med; 2021 Aug; 25(16):8039-8046. PubMed ID: 34264012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RDM1 promotes neuroblastoma growth through the RAS-Raf-MEK-ERK pathway.
    Xie G; Wu H; Cai W; Chen M; Huang W; Yan W; Chang Y
    FEBS Open Bio; 2019 Mar; 9(3):490-497. PubMed ID: 30868057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RDM1, a novel RNA recognition motif (RRM)-containing protein involved in the cell response to cisplatin in vertebrates.
    Hamimes S; Arakawa H; Stasiak AZ; Kierzek AM; Hirano S; Yang YG; Takata M; Stasiak A; Buerstedde JM; Van Dyck E
    J Biol Chem; 2005 Mar; 280(10):9225-35. PubMed ID: 15611051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
    Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
    Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleic acid-binding properties of the RRM-containing protein RDM1.
    Hamimes S; Bourgeon D; Stasiak AZ; Stasiak A; Van Dyck E
    Biochem Biophys Res Commun; 2006 May; 344(1):87-94. PubMed ID: 16630539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
    Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
    Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Li W; Huang Q; Sun D; Zhang G; Tan J
    Endocr Connect; 2017 Nov; 6(8):700-707. PubMed ID: 28939762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
    Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2.
    Du Y; Lin J; Zhang R; Yang W; Quan H; Zang L; Han Y; Li B; Sun H; Wu J
    Aging (Albany NY); 2019 Nov; 11(21):9778-9793. PubMed ID: 31727867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
    Chen S; Chen X; Xiu YL; Sun KX; Zhao Y
    PLoS One; 2015; 10(5):e0125714. PubMed ID: 25933027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.
    Llauradó M; Abal M; Castellví J; Cabrera S; Gil-Moreno A; Pérez-Benavente A; Colás E; Doll A; Dolcet X; Matias-Guiu X; Vazquez-Levin M; Reventós J; Ruiz A
    Int J Cancer; 2012 Apr; 130(7):1532-43. PubMed ID: 21520040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
    Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
    Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.
    Jazaeri AA; Ferriss JS; Bryant JL; Dalton MS; Dutta A
    Gynecol Oncol; 2010 Aug; 118(2):189-95. PubMed ID: 20462630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
    Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.